Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference

WEIFANG, China, Nov. 27 /Xinhua-PRNewswire-FirstCall/ -- ShengtaiPharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or"the Company"), a leading manufacturer and distributor of high-quality,pharmaceutical grade glucose products in China, today announced its CFO, Mr.Philips Zhang, will be presenting at the Roth Capital Phoenix Conference onNovember 29, 2007.

The date, time and location of the Company's presentation at theconference are as follows: Date: Thursday, November 29, 2007

Time: 2:45 p.m. Mountain Time

Venue: Estrella West Room, The Royal Palms Resort, Phoenix, AZ

This two-day conference will feature presentations from management teamsof more than 30 leading Chinese companies listed in the US. Interested partiesand investors may find more information for the conference by visiting thewebsite at http://www.rothcp.com .

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary ShengtaiHolding, Inc. (SHI), a New Jersey corporation, and the holding company forWeifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer andsupplier of glucose products, which include pharmaceutical grade glucose usedfor medical purposes, and glucose and cornstarch products for the food andbeverage industry and for industrial production in China. For more informationabout Shengtai Pharmaceutical, Inc. please visithttp://www.shengtaipharmaceutical.com .

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Certain statements in this press release and oral statements made bythe Company, constitute forward-looking statements for purposes of the safeharbor provisions under The Private Securities Litigation Reform Act of 1995.These statements include, without limitation, statements regarding our abilityto prepare the company for growth, the Company's planned capacity expansion in2007 and predictions and guidance relating to the Company's future financialperformance. We have based these forward-looking statements largely on ourcurrent expectations and projections about future events and financial trendsthat we believe may affect our financial condition, results of operations,business strategy and financial needs but they involve risks and uncertaintiesthat could cause actual results to differ materially from those in theforward-looking statements, which may include, but are not limited to, suchfactors as unanticipated changes in product demand especially in thepharmaceutical industry, pricing and demand trends for the Company's products,changes to government regulations, risk associated with operation of theCompany's new facilities, risk associated with large scale implementation ofthe company's business plan, the ability to attract new customers, ability toincrease its product's applications, cost of raw materials, downturns in theChinese economy, and other information detailed from time to time in theCompany's filings and future filings with the United States Securities andExchange Commission. Investors are urged to consider these factors carefullyin evaluating the forward-looking statements herein and are cautioned not toplace undue reliance on such forward-looking statements, which are qualifiedin their entirety by this cautionary statement. The forward-looking statementsmade herein speak only as of the date of this press release and the Companyundertakes no duty to update any forward-looking statement to conform thestatement to actual results or changes in the company's expectations.

For more information, please contact:

Company Contact:

Mr. Philips Zhang

CFO

Shengtai Pharmaceutical, Inc.

Tel: +86-536-629-5728

Email: shengtaicfo@hotmail.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY Office)

Email: crocker.coulson@ccgir.comSOURCE Shengtai Pharmaceutical, Inc.Company Contact - Mr. Philips Zhang, CFO of Shengtai Pharmaceutical, Inc.,+86-536-629-5728, or shengtaicfo@hotmail.com; or Investor Relations Contact -Mr. Crocker Coulson, President of CCG Elite Investor Relations,+1-646-213-1915 (NY Office), or crocker.coulson@ccgir.com, for ShengtaiPharmaceutical, Inc.